Romosozumab (Evenity): How It Compares to Bisphosphonates for Osteoporosis

What Is Romosozumab and How Does It Work?

Romosozumab is a monoclonal antibody that targets sclerostin, a protein produced by osteocytes that normally puts the brakes on new bone formation. By blocking sclerostin, romosozumab removes that brake. The result is a simultaneous surge in bone formation markers (P1NP rises sharply in the first months) and a moderate reduction in bone resorption markers (CTX falls by roughly 15 to 20%). No other approved osteoporosis drug does both things at once.

The FDA granted approval on April 9, 2019, under the brand name Evenity, co-marketed by Amgen and UCB. The approved regimen is 210 mg delivered as two consecutive 105 mg subcutaneous injections in the abdomen, upper arm, or thigh, once monthly for exactly 12 months [1]. Treatment does not extend beyond 12 months because the bone-formation effect diminishes after that window; continuing the drug without gaining additional fracture benefit carries unnecessary cardiovascular exposure.

Sclerostin inhibition is a meaningfully different mechanism from bisphosphonate therapy. Bisphosphonates are incorporated into bone matrix and released during resorption, at which point they trigger osteoclast apoptosis. That process suppresses bone turnover globally. Romosozumab, by contrast, tips the bone-remodeling balance sharply toward formation first, then restrains resorption secondarily. This is why bone mineral density (BMD) gains with romosozumab at 12 months typically exceed what any oral bisphosphonate produces in 24 to 36 months.

What the FRAME and ARCH Trials Actually Showed

Two phase III trials provide the core efficacy evidence for romosozumab.

FRAME (N=7,180) randomized postmenopausal women with a T-score between -2.5 and -3.5 at the lumbar spine or total hip to 210 mg romosozumab monthly or placebo for 12 months, followed by 12 months of denosumab 60 mg every 6 months in both groups. At 12 months, romosozumab reduced new vertebral fractures by 73% vs. placebo (P<0.001). Lumbar spine BMD increased by 13.3% vs. 0.0% with placebo, and total hip BMD rose 6.9% vs. 0.0% [2]. Clinical fracture risk fell by 36% at 12 months.

ARCH (N=4,093) directly compared romosozumab for 12 months followed by alendronate 70 mg weekly to alendronate alone for 24 months in postmenopausal women with a prior vertebral fracture and a low T-score. At 24 months, the romosozumab-then-alendronate sequence reduced new vertebral fractures by 48% relative to alendronate alone, clinical fractures by 27%, and hip fractures by 38% (P=0.02) [3]. These are head-to-head superiority data, not just placebo comparisons.

The ARCH trial also revealed the cardiovascular signal that led to the black-box warning. Serious cardiovascular events (MI, stroke, cardiovascular death) occurred in 2.5% of the romosozumab group vs. 1.9% in the alendronate group. The absolute difference was small, but the FDA and prescribers consider it clinically relevant in patients with pre-existing atherosclerotic cardiovascular disease.

Alendronate (Fosamax): The Most Widely Prescribed Bisphosphonate

Alendronate has decades of post-marketing safety data behind it. The Fracture Intervention Trial (FIT, N=2,027) showed a 47% reduction in hip fracture and a 55% reduction in vertebral fracture over 3 years in women with a prior vertebral fracture [4]. The standard dose is 70 mg orally once weekly (or 10 mg daily), taken on an empty stomach with 8 oz of plain water, remaining upright for at least 30 minutes afterward.

Alendronate's main drawbacks are gastrointestinal. Esophageal irritation, esophagitis, and difficulty swallowing affect a meaningful subset of patients. Strict dosing instructions exist precisely to reduce that risk. Long-term use beyond 5 years raises the possibility of atypical femoral fractures and osteonecrosis of the jaw, though absolute rates remain low (estimated 3.2 to 50 cases of atypical femoral fracture per 100,000 person-years) [5].

For patients who tolerate it and whose fracture risk is moderate rather than very high, alendronate remains a first-line option per the 2020 American Association of Clinical Endocrinology (AACE) guidelines, which recommend pharmacological therapy when the 10-year FRAX hip fracture probability exceeds 3% or any major osteoporotic fracture probability exceeds 20% [6].

Risedronate (Actonel): A Bisphosphonate With a Faster Onset Profile

Risedronate 35 mg once weekly or 150 mg once monthly works through the same nitrogen-containing bisphosphonate mechanism as alendronate but binds hydroxyapatite with lower affinity, which may translate to a faster offset after discontinuation. The VERT-MN trial (N=1,628) demonstrated a 41% reduction in new vertebral fractures at 3 years and a 40% reduction in non-vertebral fractures vs. placebo [7].

One practical consideration: risedronate's delayed-release formulation Atelvia can be taken immediately after breakfast, which suits patients who cannot comply with the standard 30-minute fasting window. The hip-fracture reduction data from the HIP trial showed a 30% relative risk reduction in women aged 70 to 79 with confirmed osteoporosis [8].

Risedronate shares alendronate's GI precautions and the same long-term concerns about atypical fracture. Drug holidays after 5 years of therapy are commonly considered; the AACE/ACE guidelines outline risk stratification criteria for deciding when to pause versus continue [6].

Ibandronate (Boniva): Monthly Oral or Quarterly IV Bisphosphonate

Ibandronate is available as a 150 mg oral tablet once monthly or a 3 mg intravenous injection every 3 months. The BONE trial (N=2,946) showed a 62% reduction in vertebral fractures over 3 years compared to placebo with the daily 2.5 mg dose [9]. The monthly 150 mg formulation matched that efficacy in the MOBILE trial.

A notable limitation: ibandronate has not demonstrated statistically significant hip-fracture reduction in dedicated trials. The AACE guidelines therefore position it as an alternative for patients with predominantly vertebral fracture risk or those who cannot tolerate weekly bisphosphonates, rather than as a first-line hip-fracture prevention agent [6].

The quarterly IV option appeals to patients with upper GI disease who cannot take oral bisphosphonates. Administration is a 15 to 30-second IV push in a clinic setting, which is faster than the annual zoledronic acid infusion but requires more frequent visits.

Zoledronic Acid (Reclast): Once-Yearly IV Bisphosphonate With Strong Fracture Data

Zoledronic acid 5 mg given as a single annual 15-minute IV infusion offers the most potent bisphosphonate anti-fracture data available. The HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in new vertebral fractures, a 41% reduction in hip fractures, and a 25% reduction in non-vertebral fractures at 3 years vs. placebo [10]. A separate HORIZON trial in men and women who had recently sustained a hip fracture found a 28% reduction in any new clinical fracture and, strikingly, a 28% reduction in all-cause mortality [11].

The annual dosing schedule confers an adherence advantage over weekly oral bisphosphonates. Adherence rates for oral bisphosphonates in real-world studies fall to roughly 50 to 60% at 12 months; an infusion completed in a clinical setting removes the daily or weekly pill-taking burden entirely.

Common side effects include an acute-phase reaction (fever, myalgia, arthralgia, flu-like symptoms) in up to 32% of patients after the first infusion, typically resolving within 3 days. Pre-medicating with acetaminophen 650 mg reduces the severity. Renal function must be checked before each infusion; zoledronic acid is contraindicated when creatinine clearance falls below 35 mL/min.

How Romosozumab Fits Into Sequential Therapy

Romosozumab does not stand alone. Bone-density gains earned during the 12-month treatment window erode rapidly after discontinuation unless followed immediately by an anti-resorptive agent. The FRAME extension showed that denosumab following romosozumab preserved and extended BMD gains. The ARCH data confirm that switching to alendronate after romosozumab yields fracture outcomes superior to starting with alendronate from the outset.

This "anabolic-first, anti-resorptive-second" sequence is now endorsed by the Endocrine Society's 2020 clinical practice guideline, which states: "For postmenopausal women with osteoporosis at very high risk of fracture, we suggest sequential therapy with an anabolic agent (teriparatide, abaloparatide, or romosozumab) followed by an antiresorptive agent" [12].

The practical sequencing decision rests on three variables: cardiovascular history, fracture burden, and T-score severity. A simplified decision framework used by the HealthRX clinical team assigns romosozumab as preferred anabolic therapy when (a) no prior MI or stroke within 12 months, (b) T-score at hip or spine is -2.5 or below with at least one prior fragility fracture, and (c) teriparatide or abaloparatide are cost-prohibitive or contraindicated. For patients with prior cardiovascular events, teriparatide (Forteo) 20 mcg daily or abaloparatide (Tymlos) 80 mcg daily are preferred anabolic options. After any anabolic course, transition to zoledronic acid 5 mg annually or denosumab 60 mg every 6 months is standard practice to lock in the gains.

Head-to-Head BMD Comparison Across Agents

Lumbar spine BMD gains at 12 to 24 months approximate the following ranges in clinical trial data:

• Romosozumab 210 mg monthly (12 months): 13 to 14% lumbar spine, 6 to 7% total hip
• Teriparatide 20 mcg daily (18 to 24 months): 9 to 11% lumbar spine, 3 to 4% total hip
• Zoledronic acid 5 mg yearly (12 months): 5 to 6% lumbar spine, 3 to 4% total hip
• Alendronate 70 mg weekly (12 months): 3 to 5% lumbar spine, 2 to 3% total hip
• Risedronate 35 mg weekly (12 months): 3 to 4% lumbar spine, 2 to 3% total hip
• Ibandronate 150 mg monthly (12 months): 3 to 4% lumbar spine, 1 to 2% total hip

These figures are approximations drawn from individual trial arms rather than a direct network meta-analysis; patient populations, baseline T-scores, and calcium/vitamin D co-administration differ across studies.

Monitoring, Safety, and Patient Selection

Before starting romosozumab, clinicians should review the cardiovascular history carefully. The FDA label carries a black-box warning stating that Evenity "may increase the risk of myocardial infarction, stroke, and cardiovascular death" and should not be initiated in patients who have had an MI or stroke within the past year [1]. Baseline serum calcium must be measured, and hypocalcemia must be corrected before the first injection. Dental health should be assessed given the theoretical, though low, risk of osteonecrosis of the jaw with any bone-modifying agent.

Monitoring during therapy includes:

• Serum calcium and creatinine at baseline
• DXA scan at baseline and after 12 months of romosozumab (or 2 years of bisphosphonate therapy)
• Bone turnover markers (P1NP and CTX) at 3 months to confirm pharmacological response
• Vitamin D 25-OH level; correct to above 30 ng/mL before initiating any osteoporosis therapy

Standard calcium and vitamin D supplementation (calcium 1,000 to 1 to 200 mg daily from diet plus supplement, vitamin D 800 to 1 to 000 IU daily) should accompany any pharmacological regimen per National Osteoporosis Foundation guidance [13].

Who Should Consider Romosozumab vs. a Bisphosphonate?

The choice between romosozumab and a bisphosphonate is not purely about efficacy. Cost, cardiovascular risk, and patient preference all enter the picture.

Romosozumab may be the better starting choice for patients with:

• A T-score at or below -3.0 with prior vertebral or hip fracture (very high fracture risk)
• Rapid bone loss documented on serial DXA
• Prior bisphosphonate therapy that failed to prevent fracture
• No history of MI, stroke, or severe atherosclerotic cardiovascular disease

Bisphosphonates remain appropriate first-line options for patients with:

• Moderate fracture risk (FRAX 10-year major osteoporotic fracture 10 to 20%)
• A history of MI or stroke making romosozumab contraindicated
• Cost constraints (generic alendronate 70 mg tablets cost roughly $15 to $30 per month)
• A preference for oral medication over monthly injections

The 2022 American College of Rheumatology guidelines for glucocorticoid-induced osteoporosis position bisphosphonates (oral or IV) as first-line treatment in most patients on long-term glucocorticoids, with anabolic agents reserved for very high-risk cases [14].

Practical Administration Notes for Romosozumab

Each 210 mg dose consists of two prefilled syringes (105 mg each) injected sequentially at the same visit. Injections rotate between the abdomen, upper arm, and thigh. The drug should be stored in a refrigerator at 2 to 8 degrees Celsius and allowed to reach room temperature for 30 minutes before injection. Do not freeze or shake the syringe.

Injection-site reactions occur in roughly 5% of patients and are generally mild. Arthralgias were reported in 12.6% of the romosozumab group vs. 11.0% placebo in FRAME, a statistically modest difference. Hypersensitivity reactions are uncommon but warrant standard anaphylaxis precautions in the clinic setting.

After the 12-month course ends, transition to denosumab or a bisphosphonate without delay. A gap of more than 2 months before starting anti-resorptive therapy significantly attenuates the BMD gains achieved with romosozumab.